Fosun Pharma's Subsidiary Gains Approval for Shaoyao Gancao Tang Granules

Stock News
06/29

Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) has announced that its subsidiary, Hebei Wanbang Fulin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Shaoyao Gancao Tang Granules.

The prescription for this medication originates from the classical text "Treatise on Cold Damage Diseases" by Zhang Zhongjing of the Han Dynasty and is included in the National Administration of Traditional Chinese Medicine's "Catalogue of Ancient Classical Famous Prescriptions (First Batch)."

Its primary functions are to nourish yin and blood, and to relieve spasms and pain. It is indicated for conditions involving spasmodic pain due to insufficient yin and blood and malnourishment of tendons and vessels, with symptoms such as cramps in the legs and feet and abdominal pain.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10